DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today
provided an update on the ongoing clinical trial program for DM-199, its novel
biopharmaceutical in clinical development for the treatment of diabetes and
associated complications. The company completed the first portion of its ongoing
phase I/II study of DM-199 in healthy volunteers and has now initiated dosing of
DM-199 in Type 2 diabetes patients. 


"Our development program is on track as we successfully completed acute
escalating dosing of DM-199 at multiple levels in healthy volunteers. We are now
advancing the program to evaluate the acute effects of escalating doses of
DM-199 in patients with Type 2 diabetes," said Dr. Mark Robbins, Vice President
of Clinical and Regulatory Affairs at DiaMedica. "Further, preliminary results
from the first part of the study in 18 healthy volunteers show that DM-199 was
well tolerated and demonstrated a favorable pharmacokinetic profile, supporting
potential once weekly dosing." 


The randomized, placebo-controlled, double-blinded study has now enrolled Type 2
diabetic patients to evaluate three well-tolerated dose levels based upon data
from the first portion in healthy volunteers. This second portion of the study
will evaluate acute safety, tolerability and pharmacokinetic properties for the
first time in Type 2 diabetic patients, as well as the effect of DM-199 on
improving glucose control. 


About DM-199 

DM-199 is a novel recombinant human protein known as tissue kallikrein-1
(rhKLK-1) and is currently in clinical development as a potential treatment for
Type 1 and Type 2 diabetes and associated diabetic complications. DM-199 is
believed to restore the body's regulation of four key areas disrupted in
diabetes: increasing insulin sensitivity; improving insulin secretion; improving
blood flow and immunomodulation. Through this natural physiological mechanism,
DM-199 represents a novel approach for improving glucose control and reducing
associated complications in diabetic patients. 


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM-199, is a recombinant human protein
that represents a novel approach to treating Type 1 and Type 2 diabetes.
DiaMedica is also developing a novel monoclonal antibody, DM-204 for the
treatment of Type 2 diabetes, which is in preclinical development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024